Table 1. Baseline Characteristics of Patients With 30-Day mRS 0 to 1 and mRS Greater Than 1.
| Baseline | No. (%) | |||
|---|---|---|---|---|
| Patients with mRS 0-1 (n = 8226) | Patients with mRS 2-6 (n = 2577) | |||
| Ticagrelor (n = 4136) | Placebo (n = 4090) | Ticagrelor (n = 1287) | Placebo (n = 1290) | |
| Age, mean (SD), y | 64.0 (10.6) | 64.2 (10.9) | 68.5 (11.5) | 67.7 (11.4) |
| Female | 1528 (36.9) | 1568 (38.3) | 536 (41.6) | 562 (43.6) |
| Race/ethnicity | ||||
| White | 2197 (53.1) | 2171 (53.1) | 720 (55.9) | 720 (55.8) |
| Black or African American | 12 (0.3) | 15 (0.4) | 9 (0.7) | 14 (1.1) |
| Asian | 1815 (43.9) | 1795 (43.9) | 496 (38.5) | 494 (38.3) |
| Other | 112 (2.7) | 109 (2.7) | 62 (4.8) | 62 (4.8) |
| Region | ||||
| Asia or Australia | 1828 (44.2) | 1810 (44.3) | 503 (39.1) | 496 (38.4) |
| Europe | 2073 (50.1) | 2057 (53.3) | 690 (53.6) | 693 (53.7) |
| North America | 8 (0.2) | 9 (0.2) | 3 (0.2) | 2 (0.2) |
| Central or South America | 227 (5.5) | 214 (5.2) | 91 (7.1) | 99 (7.7) |
| Blood pressure, median (IQR), mm Hg | ||||
| Systolic | 150 (134-161) | 148 (133-161) | 150 (139-167) | 150 (138-168) |
| Diastolic | 84 (79-92) | 84 (79-91) | 83 (78-90) | 83 (77-90) |
| BMI, median (IQR) | 25.9 (23.4-29.0) | 25.7 (23.2-28.9) | 25.9 (23.1-29.0) | 25.7 (23.2-29.1) |
| Medical history | ||||
| Hypertension | 3180 (76.9) | 3115 (76.2) | 1037 (80.6) | 1017 (78.8) |
| Dyslipidemia | 1545 (37.4) | 1517 (37.1) | 517 (40.2) | 488 (37.8) |
| Current smoker | 1210 (29.3) | 1105 (27.0) | 274 (21.3) | 297 (23.0) |
| Diabetes mellitus | 1109 (26.8) | 1109 (27.1) | 446 (34.7) | 403 (31.2) |
| Previous ischemic stroke | 654 (15.8) | 644 (15.7) | 238 (18.5) | 248 (19.2) |
| Previous TIA | 210 (5.1) | 184 (4.5) | 60 (4.7) | 48 (3.7) |
| Previous ischemic heart disease | 375 (9.1) | 392 (9.6) | 149 (11.6) | 127 (9.8) |
| Congestive heart failure | 143 (3.5) | 147 (3.6) | 62 (4.8) | 54 (4.2) |
| Taking aspirin prior to index event | 533 (12.9) | 483 (11.8) | 205 (15.9) | 182 (14.1) |
| Taking clopidogrel prior to index event | 52 (1.3) | 53 (1.3) | 19 (1.5) | 20 (1.6) |
| Time to randomization after onset of symptoms, h | ||||
| <12 | 1408 (34.0) | 1385 (33.9) | 373 (29.0) | 354 (27.4) |
| ≥12 | 2728 (66.0) | 2705 (66.1) | 914 (71.0) | 936 (72.6) |
| Qualifying event | ||||
| TIA | 426 (10.3) | 471 (11.5) | 53 (4.1) | 54 (4.2) |
| Ischemic stroke | 3710 (89.7) | 3619 (88.5) | 1234 (95.9) | 1236 (95.8) |
| Baseline ABCD2 score among patients with TIA as qualifying event | ||||
| ≤5 | 48 (1.2) | 60 (1.5) | 9 (0.7) | 8 (0.6) |
| 6 or 7 | 378 (9.1) | 411 (10.0) | 44 (3.4) | 46 (3.6) |
| Baseline NIHSS score among patients with ischemic as qualifying event | ||||
| ≤3 | 2679 (64.8) | 1609 (63.8) | 620 (48.2) | 627 (48.6) |
| >3 | 1031 (24.9) | 1010 (24.7) | 614 (47.7) | 609 (47.2) |
| Ipsilateral stenosis ≥30% | 805 (19.5) | 850 (20.8) | 311 (24.2) | 333 (25.8) |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); IQR, interquartile range; mRS, modified Rankin Scale score; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischemic attack.